A total of 433 patients were followed for 27 months in 43 centres after having been randomized to remote monitoring (active group) or in-clinic follow-up (control group). A first in-clinic ICD follow-up within 1 to 3 months after implantation was scheduled for all patients. Then, in the active group, patients were seen in the ambulatory department only once a year, unless an anomalous ICD function or an event of clinical concern was reported by remote monitoring and required an additional in-clinic visit. In the control group, the patients were followed in the ambulatory department at 6-month intervals.
Importantly, the ECOST trial is the first trial to show a 52% reduction of the number of patients with inappropriate shocks and a 72% reduction in the risk of hospitalizations related to inappropriate shocks, clearly underlining the effectiveness of home monitoring in ICD recipients. In addition, ECOST shows a 76% reduction in the number of charged shocks with a significant impact on ICD battery longevity.
ECOST has clinically proven with a non inferiority hypothesis that remote ICD monitoring is a safe alternative to conventional follow-up in terms of all cardiac and device related major adverse events and all cause deaths. These results are consistent with, and extend, previous findings by clearly demonstrating the safety of long-term remote ICD monitoring
Professor Kacet, Salem (Lille, France)
ESC Press Office
For background information, please contact the ESC Press Office.
For independent comment on site, please contact Kate Rees on +336 33 80 35 07.
Notes to editor
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 68,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2011
ESC Congress 2011 will take place from 27 to 31 August at the Parc des Expositions – Paris Nord Villepinte, France. Information on the scientific programme is available here. More information on ESC Congress 2011 is available from the ESC Press Office or contact us at firstname.lastname@example.org
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2011.
Hot Line II – Frontiers in Interventional Device Treatments
ECOST: Safety of implantable cardioverter defibrillator follow-up using remote monitoring: a randomized controlled trial
Edited by the ESC from material supplied by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the investigator.